# US 2013/0261073 A1 · Modulator of activity of adenylate cyclase

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0261073 A1
- Document ID: US20130261073A1
- Status: Published application
- Kind: A1
- Application number: 13/880,346
- Filed: 2011-10-20
- Published: 2013-10-03
- Earliest claimed: 2010-10-27
- Assignees: National Univeristy Corporation Yokohama National University; Public University Corporation Yokohama City University
- Inventors: Yoshihiro Ishikawa; Satoshi Okumura; Yujiro Hoshino; Seiichi Inoue
- Web page: https://patentgrep.com/patent/US20130261073A1

## CPC

- C07H 19/06: Pyrimidine radicals
- A23L 33/10: using additives (addition of substantially indigestible substances A23L33/21)
- A61K 31/7042: Compounds having saccharide radicals and heterocyclic rings
- A61K 31/7052: having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K 31/7056: containing five-membered rings with nitrogen as a ring hetero atom
- A61K 31/706: containing six-membered rings with nitrogen as a ring hetero atom
- A61K 31/7064: containing condensed or non-condensed pyrimidines
- A61K 31/7076: containing purines, e.g. adenosine, adenylic acid
- A61P 1/08: for nausea, cinetosis or vertigo; Antiemetics
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/06: Antiarrhythmics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07H 19/19: with arabinosyl as the saccharide radical
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides a novel compound capable of inhibiting cardiac adenylyl cyclase. The present invention relates to a compound represented by the following formula (I) or a pharmaceutically acceptable salt, ester or solvate thereof: where R1, R2 and R3 each independently represent a hydrogen atom or an acyl group having an acidic or basic substituent, provided that all of R1, R2 and R3 are not simultaneously a hydrogen atom. The present invention also provides a modulator of adenylyl cyclase activity, a pharmaceutical composition and a food composition, all of which comprise the above-described compound or a pharmaceutically acceptable salt, ester or solvate thereof.

## Claims

### Claim 1

A compound represented by the following formula (I) or a pharmaceutically acceptable salt, ester or solvate thereof:
where R1, R2 and R3 each independently represent a hydrogen atom or an acyl group having an acidic or basic substituent, provided that all of R1, R2 and R3 are not simultaneously a hydrogen atom.

### Claim 2 (depends on 1)

The compound according to claim 1, wherein the acyl group having an acidic or basic substituent is represented by the following formula:
B—(CH2)n—CO—
where n represents an integer from 1 to 4 and B is an acidic or basic substituent.

### Claim 3 (depends on 1, 2)

The compound according to claim 1 or 2, wherein the acidic or basic substituent is an optionally alkyl-substituted amino group, a carboxyl group or a hydroxycarbamoyl group.

### Claim 4 (depends on 1, 2, 3)

The compound according to any one of claims 1 to 3, which is represented by any of the following formulas:

### Claim 5 (depends on 1, 2, 3, 4)

A modulator of adenylyl cyclase activity, comprising the compound according to any one of claims 1 to 4 or a pharmaceutically acceptable salt, ester or solvate thereof.

### Claim 6 (depends on 5)

The modulator according to claim 5, wherein the adenylyl cyclase is cardiac adenylyl cyclase.

### Claim 7 (depends on 1, 2, 3, 4)

A pharmaceutical composition comprising the compound according to any one of claims 1 to 4 or a pharmaceutically acceptable salt, ester or solvate thereof.

### Claim 8 (depends on 7)

The pharmaceutical composition according to claim 7, which is for use in prevention and/or treatment of an indication for β-blockers.

### Claim 9 (depends on 8)

The pharmaceutical composition according to claim 8, wherein the indication for β-blockers is selected from the group consisting of heart failure, myocardial infarction, arrhythmia, angina, hypertension, and conditions and diseases associated therewith.

### Claim 10 (depends on 1, 2, 3, 4)

A food composition comprising the compound according to any one of claims 1 to 4 or a pharmaceutically acceptable salt, ester or solvate thereof.

### Claim 11 (depends on 10)

The food composition according to claim 10, which is used for antiaging and extending life span, for prevention of diseases and conditions associated therewith, or for health maintenance.

### Claim 12 (depends on 1, 2, 3, 4)

A method of preventing and/or treating an indication for β-blockers, comprising administering to a subject a pharmaceutically effective amount of the compound according to any one of claims 1 to 4 or a pharmaceutically acceptable salt, ester or solvate thereof.

### Claim 13 (depends on 1, 2, 3, 4)

Use of the compound according to any one of claims 1 to 4 or a pharmaceutically acceptable salt, ester or solvate thereof, for preventing and/or treating an indication for β-blockers.

### Claim 14 (depends on 1, 2, 3, 4)

The compound according to any one of claims 1 to 4 or a pharmaceutically acceptable salt, ester or solvate thereof, for use in a method of preventing and/or treating an indication for β-blockers.

### Claim 15 (depends on 1, 2, 3, 4)

A method of antiaging and extending life span, prevention of diseases and conditions associated therewith or health maintenance, comprising administering to a subject a pharmaceutically effective amount of the compound according to any one of claims 1 to 4 or a pharmaceutically acceptable salt, ester or solvate thereof.

### Claim 16 (depends on 1, 2, 3, 4)

Use of the compound according to any one of claims 1 to 4 or a pharmaceutically acceptable salt, ester or solvate thereof, for antiaging and extending life span, prevention of diseases and conditions associated therewith or health maintenance.

### Claim 17 (depends on 1, 2, 3, 4)

The compound according to any one of claims 1 to 4 or a pharmaceutically acceptable salt, ester or solvate thereof, for use in a method of antiaging and extending life span, prevention of diseases and conditions associated therewith or health maintenance.
